** Shares of therapy developer Immuneering rise 101.7% to $4.76 premarket
** Co says its therapy, IMM-1-104, showed an overall response rate of 43% in combination with gemcitabine during a mid-stage trial for patients with pancreatic cancer
** IMRX will expand the trial to include three combination treatment arms this year in addition to the existing three arms
** Co says it expects further trial data in Q2 2025
** Up to last close, stock down 64.8% in the previous 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。